Regeneron published first-in-human data on 8 November for a drug that is meant to be given twice a year. A single subcutaneous dose of CIDEBsiRNA reduced liver fat by 58% to 80% at week 36 in adults with metabolic dysfunction-associated steatotic liver disease (MASLD), and normalized it — below 5% fat content — in 62% of treated participants. Nobody on placebo normalized. The results appeared in the New England Journal of Medicine and were presented in an oral session at AASLD The Liver Meeting.

The trial was small: a randomized, double-blind, placebo-controlled Phase 1/2 study with 30 participants across four dose levels and 10 on placebo. Its primary goal was safety and tolerability; liver fat, measured by MRI-PDFF, was a secondary endpoint. Effects were already large at week 6 (49–72% reduction) and deepened by week 36. The placebo group's mean change was 2.9%. Ninety-three percent of treated participants crossed a 30% reduction, a threshold that has been linked to histological resolution of MASH.

Liver injury markers moved too: mean ALT fell across all dose levels, with directionally similar changes in AST. Adverse events were generally balanced with placebo and all were mild or moderate except one severe, serious case of hyperglycemia, which the company says was later attributed to a diagnosis of adult-onset Type 1 diabetes rather than the drug. There were no discontinuations, and no nausea or vomiting was reported in treated groups — a pointed detail, since those are known tolerability problems for existing MASH therapies.

The mechanism is genetic. Regeneron Genetics Center researchers identified loss-of-function variants in CIDEB that protect against liver disease; CIDEBsiRNA is designed to mimic that effect with a liver-targeted siRNA, developed with Alnylam, which receives milestones and royalties (the asset is also called ALN-CIDEB).

Context for the numbers: approved MASH therapies have reached mean liver fat reductions of 47–57% at about one year in historical trial data, according to the company's citations. Regeneron's 58–80% at 36 weeks came after one dose, not daily or weekly dosing.

The caveats are the usual ones for a first-in-human study, and they matter. Thirty patients is enough to see a strong signal and not enough to characterize a drug. Liver fat is a surrogate; biopsies and hard outcomes are being tested in Phase 2a, 2b and Phase 3 trials that are now recruiting. Nothing here is approved, and the twice-yearly claim rests on durability seen through week 36, not on a completed regimen.

Still, the direction is unambiguous: a single shot moved a surrogate endpoint further than approved oral drugs have managed in a year, in a disease that affects roughly 13 million US adults with MASH alone. The next two years of biopsy data will decide whether that translates.